In its second major deal announcement of the week following news of its proposed acquisition of Memo Therapeutics for in excess of €700m, France based listed biopharma, Ipsen, has agreed…
France: Ipsen adds to late-stage oncology pipeline with acquisition of Kartos Therapeutics
…
…






